ArticleClinical rheumatology2026
SYNOLACTATE-PLUS cross-sectional study: prospective validation of RESAS and synovial biomarkers in septic arthritis diagnosis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProspective validation of the RESAS score and its components (glucose, lactate, and lactate/glucose ratio) for the diagnosis of septic arthritis. A secondary objective was to assess the diagnostic performance of additional synovial fluid (SF) biomarkers, including calprotectin, synovial CRP and total proteins.
methodsSynovial fluid samples from patients with acute arthritis (< 30 days) were prospectively collected in the monocentric, cross-sectional SYNOLACTATE-PLUS study. Septic arthritis of native joints (SANJ) was defined according to Newman's criteria. Each sample underwent Gram staining, white blood cell count, bacterial culture and crystal analysis. Biochemical measurements included L-lactate, glucose, CRP, calprotectin and total proteins. RESAS was calculated for each patient. Diagnostic performance was evaluated using ROC curves, area under the curve (AUC), sensitivity (Se), specificity (Sp), and likelihood ratios (LR ±).
resultsAmong 208 patients, 31 had SANJ, 117 crystal-induced arthritis, and 60 other inflammatory forms. RESAS achieved an AUC of 0.905 (0.836-0.975), Se 51.6%, Sp 97.2%, LR + 18.3, and LR- 0.50 at a threshold ≥ + 4. Calprotectin showed the best diagnostic accuracy (AUC 0.944, Se 93.6%, Sp 79.4%, LR + 4.5, LR- 0.08, threshold ≥ 500 mg/L). Synovial CRP (AUC 0.753) and total proteins (AUC 0.634) were not clinically relevant. A modified RESAS combining RESAS, calprotectin, and neutrophil percentage yielded improved performance (AUC 0.961, Se 93.6%, Sp 88.0%, LR + 7.8, LR- 0.07).
conclusionRESAS demonstrated strong prospective validity for predicting septic arthritis. Among protein biomarkers, synovial calprotectin showed the highest diagnostic accuracy.
Indexed as
Identifiers
42776363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.